The digital transformation known as Pharma 4.0 is revolutionizing process optimization and decision-making within the pharmaceutical industry—at every level and across the clinical development lifecycle and supply chain. At the same time, decentralized clinical trials are now taking a leading role in clinical research. While the approach is not new, the pandemic has increased the incentive for using decentralized trials for future drug development.
We are responding with digital innovations that push the limits of efficiency, agility, and quality for our customers as we adopt networked systems, data analytics, and advanced automation. Customers will see an improved experience at every step. Activities are streamlined, from routine daily status checks or placing orders, to executing a global decentralized clinical trial or manufacturing a full product line.
Digital tools such as mobile technologies, mobile HCPs, and mobile phones are used in 77% of current decentralized trials1
Sixty to 70% of molecules in clinical development have high permeability but poor solubility; predictive modeling can help
Digital tools such as mobile technologies, mobile HCPs, and mobile phones are used in 77% of current decentralized trials1
Sixty to 70% of molecules in clinical development have high permeability but poor solubility; predictive modeling can help
From day-to-day order management and batch tracking to monthly forecasting, our digital mysupply Platform provides timely visibility and real-time collaboration tools to enable more efficient ways of working. mysupply can help you mitigate risk and keep you informed of production status by highlighting where and when your attention is most needed.
The platform gives you the ability to view current order status and batches linked to those orders, as well as risks associated with batches and orders. It also allows users to input change requests. Use it to identify delays and proactively address critical alerts and traceability of products.
What’s more, the mysupply Platform provides near real-time data sharing to enhance transparency, build trust, and encourage collaboration among stakeholders.
Forecasts
Automated forecast entry and upload with status tracking to monitor progress.
Orders
Dynamic order submission and tracking capabilities detailing order to batch connection.
Batch tracker
Improved visibility int obatch tracking/status for specific orders.
Dashboard
Up to date, transparent data for collaborative business reviews and daily performance management.
Did you know?
Decentralized clinical trials eliminate the need for a patient to visit an investigator site to receive treatment. These trials were on the rise for years before COVID-19, but their success in keeping drug development programs on course during the pandemic won these studies a new leading role in mainstream clinical development and commercialization going forward.
Sponsors are turning to an integrated supply chain solution known as direct-to-patient services to execute decentralized trial strategies. Direct-to-patient services allow patients to participate in clinical trials from their homes by providing them with study drugs and care where they live, using telemedicine and mobile or local healthcare providers.
The direct-to-patient category includes:
Fully decentralized studies, often called virtual or site-less trials. These studies bring the clinical trial to a patient’s home using a central, often virtual, coordinating facility. More than 75% of current decentralized trials use mobile technologies.1 These trials may also harness telehealth, in-home devices, sensors, and wearables, as well as digital therapeutics. The use of artificial intelligence (AI) and machine learning (ML) is also becoming more routine to facilitate diagnoses, patient stratification, and evidence generation.
Hybrid trials incorporate some virtual elements into a site-based study. These studies often access a combination of mobile clinics and patient-reported outcomes.
Our proprietary computational modeling program, PatheonTM Quadrant 2TM, analyzes your compound’s specific molecular structure and chemical characteristics, in combination with your unique target product profile. The platform consists of exclusive algorithms that incorporate a variety of different computational methods including quantum mechanics, molecular dynamics, Quantitative Structure Activity Relationship (QSAR), ADMET, statistical analysis, and internally developed models.
Using your compound’s individualized data, Quadrant 2 predictive modeling:
Quadrant 2 predictive modeling analyzes the molecular structure, as well as the physical and chemical characteristics of a compound based on the following information:
Our suite of predictive modeling tools also includes:
Contact us to understand how our Engineered Solutions can enable you to make smart decisions and de-risk your product development.
Pharma 4.0 is a new operating model for pharmaceutical factories and supply chains of the future, including new digitized and automated manufacturing approaches.
We are aligning across our network using processes that are more agile, collaborative and technology driven. The three primary ways we are doing that are as follows: Manufacturing technology and automation, including standardized processes and improved capacity; creating a digital shop floor and factory of the future; and implementing a digital toolbox and optimized processes to improve results.
Pharma 4.0 benefits to customers include: